4.5 Article

Noninvasive optical tracking of red fluorescent protein-expressing cancer cells in a model of metastatic breast cancer

Journal

NEOPLASIA
Volume 8, Issue 10, Pages 796-U12

Publisher

NEOPLASIA PRESS
DOI: 10.1593/neo.06304

Keywords

breast cancer; optical imaging; tdTomato; Xenogen; metastasis

Categories

Funding

  1. NCI NIH HHS [P50 CA103175] Funding Source: Medline

Ask authors/readers for more resources

We have evaluated the use of the Xenogen IVIS 200 imaging system for real-time fluorescence protein based optical imaging of metastatic progression in live animals. We found that green fluorescent protein expressing cells ( 100 x 10(6)) were not detectable in a mouse cadaver phantom experiment. However, a 10-fold lower number of tdTomato-expressing cells were easily detected. Mammary fat pad xenografts of stable MDA-MB-231-tdTomato cells were generated for the imaging of metastatic progression. At 2 weeks postinjection, barely palpable tumor burdens were easily detected at the sites of injection. At 8 weeks, a small contralateral mammary fat pad metastasis was imaged and, by 13 weeks, metastases to lymph nodes were detectable. Metastases with nodular composition were detectable within the rib cage region at 15 weeks. 3-D image reconstructions indicated that the detection of fluorescence extended to approximately 1 cm below the surface. A combination of intense tdTomato fluorescence, imaging at >= 620 nm ( where autofluorescence is minimized), and the sensitivity of the Xenogen imager made this possible. This study demonstrates the utility of the noninvasive optical tracking of cancer cells during metastatic progression with endogenously expressed fluorescence protein reporters using detection wavelengths of >= 620 nm.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available